Key statistics
On Friday, Crinetics Pharmaceuticals Inc (6Z4:FRA) closed at 47.60, -4.80% below its 52-week high of 50.00, set on Jul 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.60 |
---|---|
High | 47.60 |
Low | 47.60 |
Bid | 48.20 |
Offer | 48.60 |
Previous close | 48.80 |
Average volume | 22.78 |
---|---|
Shares outstanding | 80.04m |
Free float | 76.89m |
P/E (TTM) | -- |
Market cap | 4.22bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 07:12 BST.
More ▼
Announcements
- Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
- Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
- Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
- Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
- EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
More ▼